

December 4, 2024

**National Stock Exchange of India Limited**

'Exchange Plaza', C-1, Block G,  
Bandra Kurla Complex  
Bandra (E), Mumbai 400 051

Sub: Application under Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**Listing Regulations**") for the proposed Composite scheme of amalgamation amongst Sequent Scientific Limited ("**Company**"), Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, S.V. Labs Private Limited, Vindhya Organics Private Limited, Viyash Life Sciences Private Limited, Geninn Life Sciences Private Limited and Sequent Research Limited and their respective shareholders and creditors under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ("**Scheme**")

Dear Sir/ Madam,

Ref: Report on Complaints pursuant to Regulation 6 of SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023 on (i) Scheme of Arrangement by Listed Entities and (ii) Relaxation under Sub- rule (7) of rule 19 of the Securities Contracts (Regulation) Rules, 1957 ("**SEBI Master Circular**")

This is in reference to the Scheme filed by the Company pursuant to Regulation 37 of the Listing Regulations with BSE Limited ("**BSE**") and National Stock Exchange of India Limited ("**NSE**").

As per Paragraph 6.a of Part I of the SEBI Master Circular, the Company is required *inter alia* to submit a 'Report on Complaints' containing the details of complaints received by the Company on the Scheme from various sources within 7 days of expiry of 21 days from the date of uploading of the draft Scheme and related documents on the website of the relevant stock exchange.

The period of 21 days from the date of uploading of the draft Scheme along with related documents by NSE on its website i.e. November 11, 2024, has expired on December 2, 2024, accordingly, we enclose herewith a 'Report on Complaints', as Annexure-1 to this letter.

The Report on Complaints is also being uploaded on the website of the Company, at <https://sequent.in/investor-relation/composite-scheme-of-arrangement/> as per requirement of the aforementioned said SEBI Master Circular.

We request you to take the above on record as compliance under the applicable provisions of the Listing Regulations and SEBI Master Circular.

**For SeQuent Scientific Limited**

**Phillip Trott**  
**Company Secretary & Compliance Officer**  
**Membership No. FCS 7403**

SeQuent Scientific Limited

Registered Office: 301, 3<sup>rd</sup> Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra India

Tel No.: +91-22-4111-4777 | CIN: L99999MH1985PLC036685

Website: <http://www.sequent.in> | Email Id: [investorrelations@sequent.in](mailto:investorrelations@sequent.in)

**ANNEXURE 1**  
**COMPLAINTS REPORT**

**Period of Complaints Report: November 11, 2024 to December 2, 2024**

**Part A**

<b>Sr. No.</b>	<b>Particulars</b>	<b>Number</b>
1	Number of complaints received directly	Nil
2	Number of complaints forwarded by Stock Exchanges / SEBI	Nil
3	Total Number of complaints/comments received (1+2)	Nil
4	Number of complaints resolved	Not Applicable
5	Number of complaints pending	Not Applicable

**Part B**

<b>Sr. No.</b>	<b>Name of complainant</b>	<b>Date of complaint</b>	<b>Status</b>
<b>Not applicable</b>			

**For SeQuent Scientific Limited**

**Phillip Trott**  
**Company Secretary & Compliance Officer**  
**Membership No. FCS 7403**

**SeQuent Scientific Limited**

**Registered Office:** 301, 3<sup>rd</sup> Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra India

**Tel No.:** +91-22-4111-4777 | **CIN:** L99999MH1985PLC036685

**Website:** <http://www.sequent.in> | **Email Id:** [investorrelations@sequent.in](mailto:investorrelations@sequent.in)